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Background: PNH is associated with abdominal vein thrombosis, which can cause splenomegaly and
hypersplenism. The combination of thrombosis, splenomegaly, and thrombocytopenia (TST) is challenging
because anticoagulants are indicated but thrombocytopenia may increase the bleeding risk. Splenectomy
could alleviate thrombocytopenia and reduce portal pressure, but it can cause post-operative thromboses and
opportunistic infections. We therefore sought to determine whether selective splenic artery embolization (SSAE)
is a safe and effective alternative to splenectomy for TST in patients with PNH.
Methods: Four patients with PNH and TST received successive rounds of SSAE. By targeting distal vessels for
occlusion, we aimed to infarct approximately 1/3 of the spleen with each procedure.
Results: Three of 4 patients had an improvement in their platelet count, and 3 of 3 had major improvement in
abdominal pain/discomfort. The one patient whose platelet count did not respond had developed marrow
failure, and she did well with an allo-SCT. Post-procedure pain and fever were common and manageable; only
one patient developed a loculated pleural effusion requiring drainage. One patient, who had had only a partial
response to eculizumab, responded to SSAE not only with an improved platelet count, but also with an increase
in hemoglobin level and decreased transfusion requirement.
Conclusions: These data indicate that SSAE can decrease spleen size and reverse hypersplenism, without
exposing the patient to the complications of splenectomy. In addition, SSAE probably reduces the uptake of
opsonised red cells in patients who have had a limited response to eculizumab, resulting in an improved quality
of life for selected patients.
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PNH is characterized by the triad of hemolytic anemia, cy-
topenias and a high risk of venous thrombosis. This is a re-
sult of the expansion of a stem cell clone with an acquired
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unless otherwise stated.synthesis of glycosylphosphatidylinositol (GPI), and there-
fore a deficiency of all GPI-linked proteins on the surface
of circulating blood cells. Since two complement inhibi-
tors, CD55 and CD59, are GPI-linked, this results in intra-
vascular complement-mediated lysis of red cells. A similar
defect on the surface of platelets probably contributes to
the marked thrombophilic state of these patients, which
particularly involves the intra-abdominal veins [2-7].
Splenomegaly, when it occurs in PNH, is commonly a
consequence of splenic, hepatic, or portal vein thrombosis;
this can result in hypersplenism and can contribute to cy-
topenias. We have particularly noted the combination ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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we term TST) in patients with PNH to be challenging,
because splenectomy is hazardous in the presence of
portal hypertension, and it may be complicated by further
thrombosis [8]. Selective splenic artery embolization (SSAE)
represents a potentially safer alternative, available since
the 1970’s, when Spigos et al [9] used this approach to
treat renal transplant patients with hypersplenism and
persistent leucopenia. Subsequently, SSAE was used in
children [10] and in adults with hypersplenism from
biliary atresia [11], thalassemia [12,13], and idiopathic
thrombocytopenia purpura [14]. Of note, this approach
has been favorably compared with splenectomy in a se-
lect group of patients in a randomized trial [15]. To our
knowledge, only one patient with PNH—who had com-
plications of a liver transplantation for Budd Chiari
syndrome—has previously been treated in this way [16],
which resulted in a decrease in ascites. Here we describe
four patients with PNH, all of whom had splenomegaly,
intra-abdominal thromboses and severe thrombocytopenia,
who were treated with SSAE. Three of the patients had a
substantial and sustained clinical improvement, and the
fourth patient was successfully treated with an allogeneic
stem cell graft.
Results
All 4 patients had hemolytic PNH at the time of SSAE
treatment. The main findings and hematologic parame-
ters are shown in Table 1. Here we give brief summaries.
Patient 1 was referred to us in 1999 with a diagnosis
of PNH complicated by DVT (Table 1) and a sonogram
showed cavernous transformation of the portal vein,
multiple collaterals, markedly attenuated right and mid-
dle hepatic veins, with normal flow demonstrated only
in the left hepatic vein. She was having frequent attacks of
abdominal pain, and in 2000 repeat imaging showed that
the spleen had increased to 21.2 cm; endoscopy demon-
strated non-bleeding gastric varices but no esophageal vari-
ces. The patient was given nadolol to reduce portal pressure
and therapeutic doses of low molecular weight heparin.
The combination of thrombocytopenia, varices, and antic-
oagulation implied a high long-term risk of hemorrhage,
and we considered that the thrombocytopenia was largely
the result of hypersplenism. Therefore, in April 2000 the
patient underwent selective embolization of the inferior
branches of the splenic artery, using gelfoam pledgets
and microcoils (Figure 1). The patient developed fever
and severe abdominal pain in the LUQ, which subsided
within 48 hours. A repeat MR venogram showed a de-
crease in spleen size to 18.3 cm, with multiple infarcts
in the mid to lower pole of the spleen, and the platelet
count rose to 61 × 103/ul. A second SSAE procedure
was carried out in January 2001, targeting the lower
pole of the spleen, as well as some peripheral superiorbranches. This time there was much less pain; repeat
imaging estimated a spleen size of 15 cm, and the plate-
let count was now in the range from 60 to 80 × 103/ul.
Furthermore, there was now almost complete reso-
lution of the abdominal pain. In November 2002 a third
SSAE procedure was carried out: this time the 2
remaining major branches of the splenic artery were
embolized, as well as a previously embolized branch
that seemed to have recanalized. A sonogram estimated
the spleen size at 12 cm; the platelet count increased to
162,000 × 103/ul and has been above 100 × 103/ul ever
since. The patient is currently on eculizumab and
fondaparinux.
Patient 2 was referred in 1999 because of PNH, an en-
larged spleen, and thrombocytopenia (Table 1). Over the
previous 4 years she had had 3-6 hospitalizations per
year for abdominal pain, and occasional transfusions of
packed red blood cells. An MR venogram showed an en-
larged liver (18.7 cm) with heterogeneous texture, and
thrombosis in the distal right, middle, and left hepatic
veins, with attenuation of the proximal hepatic veins,
consistent with an early Budd Chiari syndrome. There
was also non-occlusive thrombosis in the left portal vein,
as well as a narrowed right anterior portal vein. It was
considered that thrombosis was too long-standing for
thrombolytic therapy [17], and the patient was started on
coumadin. By January 2000, the platelet count had fallen to
42 × 103/ul. It was thought that the thrombocytopenia
could be due in part to decreased production, and in part
to hypersplenism. Therefore, the patient was treated with
equine ATG, followed by cyclosporine. Over the next sev-
eral years there was no improvement in thrombocytopenia,
and the patient’s anticoagulation had to be periodically dis-
continued because of menorrhagia. MR venogram studies
demonstrated thrombosis in the left portal vein and splenic
vein, as well as splenomegaly. The first SSAE procedure
(Figure 2) was complicated by severe pain and a large left
sided pleural effusion, which required readmission for
thoracentesis and then a VATS procedure for an entrapped
lung. Since the platelet count did not change significantly,
a second SSAE was carried out, without complications.
Following this, the spleen size was reduced, the abdominal
pains were greatly alleviated, and the patient was able to
return to work full time. However, the thrombocytopenia
did not improve and we had to conclude, after a repeat
bone marrow, that it had not responded to SSAE because
it was due, at least in large part, to decreased platelet pro-
duction from bone marrow failure. The patient was there-
fore given rabbit ATG treatment, and did not respond. She
then received an unrelated allogeneic SCT, engrafted, and
is now in good health.
Patient 3 was referred because of splenic vein throm-
bosis and an enlarged spleen measuring 36 × 12.5 ×
14 cm; a CT showed collateralization of venous flow and
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Figure 1 Patient 1: (A) Serial Coronal MRI’s of the abdomen. The splenomegaly is seen to progressively resolve, and there is correction of the
displacement of the left kidney over time. (B) Angiograms of the spleen pre and post procedure, demonstrating insertion of radiopaque material
in arterial branches (→) and lack of distal opacification.
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phil counts, which needed intermittent support with G-
CSF. Because the very low platelet counts did not respond
well to platelet transfusions, it seemed likely that cytope-
nias were secondary to splenic sequestration. Therefore, an
SSAE procedure was carried out (Figure 3), whereby the
lower branch of the splenic artery was embolized by gelatinFigure 2 Patient 2, serial axial CT scans of the abdomen, demonstrati
branches of the splenic artery (→), which has resulted in wedge shap
resolve, and there is progressively less impingement upon the left kidney.sponge and stainless steel coils. Approximately ½ of the
spleen was thought to have been embolized, and the pa-
tient tolerated the procedure well. Within 2 weeks the
platelet count had risen to 68,000 × 103/ul, but subse-
quently it gradually fell to 35,000. Her physicians did not
consider that her platelet count was adequate for anticoa-
gulation, and a second embolization was considered butng a heterogeneous liver, radiopaque material placed in the
ed splenic infarctions (v). The splenomegaly is seen to progressively
Figure 3 Patient 3, pre and post-procedure axial CT scans with contrast, demonstrating massive splenomegaly, the successful
placement of radiopaque material in branches of the splenic artery (→), resulting in splenic infarction (v).
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started on eculizumab, which is known to reduce the risk
of thrombotic complications of PNH [18], and this also
helped her to achieve transfusion-independence. Since the
SSAE procedure, the patient has not had any further
thrombotic complications. The average platelet count has
been 44,000 × 103/ul, whereas the neutrophil count was
not affected and has averaged approximately 0.64 × 103/ul.
Patient 4 was referred in 1998 because of severe
hemolytic anemia and a history of superior sagittal sinus
thrombosis, and PNH was diagnosed. For 7 years the pa-
tient received transfusion support every 5 weeks, and
she was maintained throughout her course on oral anti-
coagulants or low molecular weight heparin. Exacerba-
tions of hemolysis with hemoglobinuria were rare, and
overall the patient had a good quality of life. In 2007 the
patient reported fatigue, abdominal pain, and headaches.
At the same time, the transfusion requirement increased
to 1 unit of red blood cells every week. Pancytopenia
progressively developed (see Table 1), and no HLA com-
patible donor was available. Eculizumab was started; fa-
tigue and headaches subsided, but the patient remained
transfusion dependent (1 unit of PRC every 3-4 weeks)
and she still had abdominal pain. Reticulocytes remained
elevated, LDH and unconjugated bilirubin were slightly
above normal, and the direct antiglobulin test (DAT)
was positive with anti-C3d, whereas the platelet count
decreased further to <10 × 103/ul. An abdominal ultra-
sound study showed marked splenomegaly (22 cm), ob-
literation of the right and middle hepatic veins and
obstruction of the inferior vena cava. It seemed likely
that both the thrombocytopenia and the high transfusion
requirement were at least to some extent secondary to
hypersplenism [19,20] .SSAE was performed in three successive procedures
carried out in June, July and November 2008, respec-
tively. Each procedure achieved partial embolization of
the spleen with coils. Except for a chest infection after
the second procedure, the patient tolerated SSAE well.
The platelet counts gradually recovered (Figure 4) and
three years later stabilized at a level of 80-100,000 × 103/ul.
There was also a decrease in reticulocytes, LDH and
unconjugated bilirubin. On the other hand, there was a
further increase in the percentage of PNH III red cells.
These findings, taken together, suggested that extravas-
cular hemolysis was reduced considerably. In keeping
with this, the transfusion requirement is now approxi-
mately 1 unit of red cells every 3 months; furthermore,
her abdominal pains have resolved, and the patient’s
quality of life has now improved dramatically.
Discussion
SSAE is an effective alternative to splenectomy for TST in
PNH patients
All four of our patients had thrombosis, splenomegaly,
and thrombocytopenia (TST), a triad that emerges as a
syndrome of its own. Splenectomy could be used to treat
TST and, by reducing blood flow into the portal system,
it could reduce portal pressures. However, splenectomy
can be complicated by post-operative thromboses, even
in patients who do not have a hypercoagulable state. In
addition, total ablation of splenic function is not desi-
rable in patients with PNH, since they may be already
neutropenic, may have impaired neutrophil function,
and may be immunosuppressed by treatments such as
ATG, cyclosporine or eculizumab. SSAE emerges, then,
as an alternative to splenectomy, with the aim to reduce
spleen function through the occlusion, beyond the
Figure 4 Time course of hematological parameters of patient 4 in relation to eculizumab treatment and SSAE treatment. Eculizumab
was started in December 2007. SSAE of the three main branches of the splenic artery was performed in June, July, and November 2008. It is seen
that the rather severe thrombocytopenia did not respond to eculizumab (nor was that expected), but it did respond to SSAE; the transfusion
requirement decreased somewhat on eculizumab but much more after SSAE.
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branches are end-arteries and therefore this procedure
produces infarction of the splenic parenchyma, with
consequent reduction of spleen size.
Here we demonstrate that TST is amenable to treat-
ment by SSAE. Following this procedure, all 4 patients
had a marked reduction in spleen size, and 3 out of 4
had a clinically significant increase in platelet counts. All
3 of the patients who had had disabling recurrent attacks
of abdominal pain or discomfort from splenomegaly re-
ported a substantial improvement in symptoms. We at-
tribute the improvement in the platelet count to a
correction of hypersplenism. The mechanism for the re-
lief of pain is less clear: decreased arterial flow to the
spleen will decrease the venous return into the portal
system, which may ameliorate portal hypertension. Al-
ternatively, decreased spleen size may relieve pressure on
the splenic capsule. The clinical and hematological im-
provement was long-lasting, with a follow-up time of 3.5
to 12 years. The only patient whose thrombocytopenia
was not corrected had bone marrow failure in addition to
hypersplenism, and therefore she was treated by BMT.
Even in her case, the procedure was likely to have been
beneficial, because the correction of hypersplenism prior
to the BMT may well have facilitated blood count reco-
very post BMT.
Radiologic, anatomic, and physiologic considerations
pertinent to SSAE
Since the purpose of SSAE is to reduce spleen function,
we need to consider the anatomy of the splenic vascula-
ture. The main splenic artery gives off many small
branches to the stomach and pancreas before dividing,
at the splenic hilum, into several branches. Althoughthere may be a few anastomoses near the hilum, there
is little collateral flow within the substance of the
spleen: i.e., the branches of the main splenic artery are
end-arteries [21]: therefore when one of them is oc-
cluded beyond the hilum, the typical result is infarction
of the parenchyma that was supplied by that branch.
Our purpose in the use of SSAE in these patients was
fundamentally different from that of splenic artery
embolization used to arrest hemorrhage secondary to
splenic trauma. In that case, the objective is to occlude
the vessel proximally in order to diminish the pressure
head and facilitate normal hemostasis, while at the same
time preserving tissue viability, which is made possible
by collateral pathways. In contrast, in our patients, the
purpose is to diminish the volume of splenic paren-
chyma through infarction.
For achieving this, several agents can been used, in-
cluding gelfoam, polyvinyl alcohol particles, silastic
spheres, and balloon catheters. We have preferred gel-
foam because it is easy to cut into pledgets small enough
to occlude branches of the splenic artery, and because of
success reported by several authors. In conjunction with
the gelfoam, we also used micro-coils in order to inhibit
recanalization. The use of coils for treating hypersplen-
ism by more proximal occlusion of the splenic artery has
been abandoned, because the effect on platelet and
WBC counts has proven short-lived, on account of the
development of collaterals [22].
To avoid infarction of too large a volume of splenic pa-
renchyma (that can result in splenic abscess formation,
splenic rupture, pneumonia, and sepsis) we employed a
stepwise approach of embolization, aimed to infarct about
one-third of the entire spleen, fully aware that we would
need to carry out additional rounds. It is preferable to
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ing and thus the development of a left pleural effusion
(see Harned et al. [23]), which did occur nevertheless in
one of our patients.
The most significant clinical side effect of SSAE was se-
vere pain radiating from the left upper quadrant, presum-
ably from nerve endings in the splenic capsule, and it
requires medication, including opiates, which, if given in
time, can prevent splinting; we recommend delivery intra-
venously by patient controlled analgesia (PCA). Here, sub-
sequent embolizations were associated with less pain than
the initial procedure. Strict aseptic technique is impera-
tive, and we administered peri-procedural antibiotics. An-
ticoagulants should be stopped prior to the procedure,
and then re-started, as we have done, to avoid hemorrhage
at the site of arterial entry, and perhaps also to allow a
brief period of time for a thrombus to form in the
embolized artery. Since splenic rupture is a potential
complication, a surgical team with expertise in hepato-
biliary diseases should be consulted prior to the procedure
and remain available. Because SSAE never removes all of
the splenic parenchyma, the risk of overwhelming infection
is probably very low; however, pre-procedure vaccinations
are reasonable, in the event that complications require a
splenectomy. For those on eculizumab, the administration
should remain on schedule.
Role of SSAE in the management of complications of PNH
There are several reasons that the incidence of TST in
PNH will decrease over time: (i) eculizumab, a humanized
monoclonal antibody against C5, blocks complement-
mediated intravascular hemolysis [24] and considerably
decreases the risk of thrombosis [18]. In all of our pa-
tients, TST developed before eculizumab was available;
(ii) primary prophylaxis with anticoagulation – though
it is not itself free of risk – can reduce the risk of
thrombosis [25]: our patients were referred to us having
not been on anticoagulant prophylaxis; (iii) In a group
of 9 select patients with recent thromboses, we have
shown that thrombolysis is effective for restoring vessel
patency [17], and this could prevent TST (none of the 4
patients reported here received thrombolytics on account
of their long duration of thromboses); (iv) as eltrombopag
is developed as a potential treatment for marrow failure
syndromes, it is possible that this will emerge as an alter-
native treatment for thrombocytopenia in patients with
TST. Nevertheless, even in the current era, we expect that
there will still be some patients who first present having
already had long-standing venous thromboses and TST,
and we believe that SSAE will remain an important treat-
ment for them.
Moreover, the clinical course of patient 4 (Figure 4)
suggests that here we may have opened up a role for
SSAE for a specific subset of PNH patients – those whohave had only a partial response to eculizumab. Persist-
ent transfusion dependence occurs in about 15% of pa-
tients with hemolytic PNH treated with eculizumab [26]:
sometimes this can be explained by rapid drug metabol-
ism, or by marrow failure– but probably in the majority
of cases it is due to extravascular hemolysis primarily in
the spleen, as a result of deposition of C3d on red cells,
leading to opsonization [19], and very recently, it has
been shown that genetic polymorphism of the comple-
ment receptor 1 gene is a determinant of response to
eculizumab [27]. Indeed, in patient 4, after SSAE, there
was not only a marked decrease in spleen size and an in-
crease in platelet counts– but also a significant reduc-
tion in red cell transfusion requirement. We believe that,
like the patient reported by Ristano et al. who had a
good response to splenectomy [20], this patient bene-
fited from a reduction in splenic size—with the advan-
tage that splenic function was not completely lost. If the
only indication for SSAE were to decrease splenic uptake
of opsonized red cells in those on eculizumab, it will be
important to select patients very carefully. One exclusion
criterion should be reticulocytopenia (indicative of mar-
row failure); whereas ongoing transfusion requirement,
progressive iron overload, an elevated reticulocyte count
and bilirubin level, as well as documentation of C3d on
the surface of red cells (based on a Coombs test or flow
cytometry) might be regarded as essential inclusion cri-
teria for SSAE in the absence of TST.
Conclusions
We have shown that SSAE, carried out in sequential
steps, is of benefit to patients with PNH who have TST
and may have hypersplenism. We have observed clinic-
ally significant resolution of pain in all cases, and we
have documented objective responses in terms of spleen
size and platelet counts in most of the cases. In addition,
for patients who remain transfusion dependent on eculi-
zumab on account of extravascular hemolysis, SSAE
may provide the extra benefit of alleviating transfusion
requirement and is probably preferable to splenectomy.
Methods
Institutional Review Board approval was obtained for the
maintenance of the database from which this paper was
written, according to HIPPA guidelines. We identified pa-
tients with PNH complicated by TST who were thought
to be not amenable to thrombolysis on the basis of long
duration of thromboses. Patients who were thought to
have a major component of immune mediated marrow
failure were either excluded or first treated with immu-
nosuppression prior to the procedure.
A stepwise and selective approach was chosen for
embolization. Particularly, we aimed to occlude distal in-
ferior branches of the splenic artery with the first
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pleural effusion from developing. Our objective was to
infarct no more than 1/3 of the spleen with the first pro-
cedure and ultimately no more than 2/3 of the spleen
overall by the end of the final procedure. Prior to the
procedure, anticoagulants were briefly discontinued,
peri-procedural antibiotics were administered, and the
patients were treated with intravenous fluids until their
oral intake recovered. Patients were hospitalized for the
procedure, and intravenous opiates– including delivery
by patient controlled analgesia– was given promptly to
relieve pain and prevent splinting, and acetaminophen
was given for post-procedure fever.
Abbreviations
TST: Thrombosis, splenomegaly, and thrombocytopenia; SSAE: Selective
splenic artery embolization; PNH: Paroxysmal nocturnal hemoglobinuria;
LUQ: Left upper quadrant; DAT: Direct anti-globulin test.
Competing interests
DJA has served on a scientific advisory board and speakers bureau for
Alexion, Inc. LL has served on a scientific advisory board for Alexion in the
past and has given unpaid lectures in some Alexion-sponsored events.
The other authors have no relevant disclosures.
Authors’ contributions
DJA, API, and KB contributed equally to this work. DJA, API, KB, RF, and LL
conceived the study and wrote the manuscript. These authors, with the
assistance of GFT, WB, FN, MSD, CG, and OZ, referred patients to the study
and gathered clinical data. KB and FMS performed the radiologic procedures
described. All authors read and approved the final manuscript.
Authors’ information
David J Araten, Anna Paola Iori and Karen Brown: Joint first authors.
Author details
1Division of Hematology, NYU School of Medicine, and the New York Harbor
VA Medical Center, New York, NY, USA. 2Department of Hematology,
“Sapienza” University of Rome, Rome, Italy. 3Department of Radiology
Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4Department of
Radiological Sciences, Vascular and Interventional Unit, “Sapienza” University
of Rome, Rome, Italy. 5Department of Haematology, Hadassah Medical
School, Jerusalem, Israel. 6Istituto Toscano Tumori, Firenze, Italy. 7Laura and
Isaac Perlmutter Cancer Center, NYU Langone Medical Center, 240 East 38th
Street, 19th floor, New York, NY 10016, USA.
Received: 8 October 2013 Accepted: 7 February 2014
Published: 27 March 2014
References
1. Miyata T, Takeda J, Iida Y, Yamada N, Inoue N, Takahashi M, Maeda K, Kitani
T, Kinoshita T: The cloning of PIG-A, a component in the early step of
GPI-anchor biosynthesis. Science 1993, 259:1318–1320.
2. Araten D, Thaler H, Luzzatto L: High incidence of thrombosis in African-
American and Latin-American patients with Paroxysmal Nocturnal
Haemoglobinuria. Thromb Hemost 2005, 93(1):88–91.
3. Dixon R, Rosse W, Thorpe A: Mechanism of Complement-Mediated
Activation of Human Blood Platelets in Vitro. J Clin Invest 1977,
59:360–368.
4. Jin J, Tooze J, Marsh J, Gordon-Smith E: Glycosylphosphatidyl-inositol (GPI)-
linked protein deficiency on the platelets of patients with aplastic anaemia
and paoxysmal nocturnal haemoglobinuria: two distinct patterns
correlating with expression on neutrophils. Br J Haematol 1997, 96:493–496.
5. Sims P, Faioni E, Wiedmer T, Shattil S: Complement Proteins C5b-9
Cause Release of Membrane Vesicles from the Platelet Surface That
Are Enriched in the Membrane Receptor for Coagulation Factor Vaand Express Prothrombinase Activity. J Biol Chem 1988,
263:18205–18212.
6. Wiedmer J, Hall S, Ortel T, Kane W, Rosse W, Sims P: Complement-Induced
Vesiculation and Exposure of Membrane Prothrombinase Sites in Platelets
of Paroxysmal Nocturnal Hemoglobinuira. Blood 1993, 82:1192–1196.
7. Zimmerman T, Kolb W: Human Platelet-Initiated Formation and Uptake
of the C5-9 Complex of Human Complement. J Clin Invest 1976,
57:203–211.
8. Kinjo N, Kawanaka H, Akahoshi T, Tomikawa M, Yamashita N, Konishi K,
Tanoue K, Shirabe K, Hashizume M, Maehara Y: Risk factors for portal
venous thrombosis after splenectomy in patients with cirrhosis and
portal hypertension. Br J Surg 2010, 97(6):910–916.
9. Spigos D, Jonasson O, Mozes M, Capek V: Partial splenic embolization in
the treatment of hypersplenism. Am J Roentgenol 1979, 132:777–782.
10. Kumpe D, Rumack C, Pretorius D, Stoecker T, Stellin G: Partial splenic
embolization in children with hypersplenism. Radiology 1985, 155:356–362.
11. Ando H, Ito T, Nagaya M: Partial splenic embolization decreases the
serum bilirubin levels in patients with hypersplenism following the
Kasai procedure for biliary atresia. J Am Coll Surg 1996, 182:206–210.
12. Politis C, Spigos D, Georrgiopoulou P, Vrettou H, Economidou I, Germenis
A, Richardson C, Papaevangelou G: Partial splenic embolization for
hypersplenism of Thalessemia major: five year follow-up. Br Med J 1987,
294:665–667.
13. Stanley P, Shen T: Partial embolization of the spleen in patients with
Thalassemia. JVIR 1995, 6:137–142.
14. Miyazaki M, Itoh H, Kaiho T, Ohtawa S, Ambiru S, Hayashi S, Nakajima N,
Oh H, Asai T, Iseki T: Partial splenic embolization for treatment of chronic
idiopathic thrombocytopenic purpura. Am J Roentgenol 1994, 163:123–126.
15. Mozes M, Spigos D, Pollak R, Abejo R, Pavel D, Tan W, Jonasson O:
Partial splenic embolization, an alternative to splenectomy–results of a
prospective, randomized study. Surgery 1984, 96:694–702.
16. Chang C, Singal A, Ganeshan S, Schiano T, Lookstein R, Emre S: Use of
Splenic Artery Embolization To Relieve Tense Ascites Following Liver
Transplantation in a Patient with Paroxysmal Nocturnal Hemoglobinuria.
Liver Transpl 2007, 13:1532–1537.
17. Araten D, Notaro R, Thaler H, Kernan N, Boulad F, Castro-Malaspina H, Small
T, Scaradavou A, Magnan H, Prockop S, Chaffee S, Gonsky J, Thertulien R,
Tarquini R, Luzzatto L: Thrombolytic therapy is effective in paroxysmal
nocturnal hemoglobinuria: a series of nine patients and a review of the
literature. Haematologica 2012, 97(3):344–352.
18. Hillmen P, Muus P, Dührsen U, Risitano A, Schubert J, Luzzatto L,
Schrezenmeier H, Szer J, Brodsky R, Hill A, Socié G, Bessler M, Rollins S, Bell L,
Rother R, Young N: Effect of the complement inhibitor eculizumab on
thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Blood 2007, 110(12):4123–4128.
19. Risitano A, Marando L, Seneca E, Rotoli B: Hemoglobin normalization after
splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated
by eculizumab. Blood 2008, 112:449–451.
20. Risitano A, Notaro R, Marando L, Serio B, Ranaldi D, Seneca E, Ricci P, Alfinito
F, Camera A, Gianfaldoni G, Amendola A, Boschetti C, DiBona E, Fratellanza
G, Barbano F, Rodeghiero F, Zanella A, Iori A, Selleri C, Luzzatto L, Rotoli B:
Complement fraction 3 binding on erythrocytes as additional
mechanism of disease in paroxysmal nocturnal hemoglobinuria patients
treated by eculizumab. Blood 2009, 113(17):4094–4100.
21. Hilleren D: In Embolization of the spleen for the treatment of hypersplenism
and in portal hypertension. Edited by Kadir S. Philadelphia: B.C Decker;
1991:493–497.
22. Wallace S, Gianturco C, Anderson J, Goldstein H, Davis J, Bree R:
Therapeutic vascular occlusion utilizing steel coil technique: clinical
applications. Am J Roentgenol 1976, 127:381–387.
23. Harned R, Thompson H, Kumpe D, Narkewicz M, Sokol RJ: Partial Splenic
Embolization in Five Children with Hypersplenism: Effects of Reduced-
Volume Embolization on Efficacy and Morbidity. Radiology 1998, 209:803–806.
24. Hillmen P, Young N, Schubert J, Brodsky R, Socié G, Muus P, Röth A, Szer J,
Elebute M, Nakamura R, Browne P, Risitano A, Hill A, Schrezenmeier H, Fu C,
Maciejewski J, Rollins S, Mojcik C, Rother RP, Luzzatto L: The Complement
Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J
Med 2006, 355(12):1233–1243.
25. Hall C, Richards S, Hillmen P: Primary prophylaxis with warfarin prevents
thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003,
102(10):3587–3591.
Araten et al. Journal of Hematology & Oncology 2014, 7:27 Page 9 of 9
http://www.jhoonline.org/content/7/1/2726. Luzzatto L, Gianfaldoni G, Notaro R: Management of Paroxysmal Nocturnal
Haemoglobinuria: a personal view. Br J Haematol 2011, 153:709–720.
27. Rondelli T, Risitano A, de Latour RP, Sica M, Peruzzi B, Ricci P, Barcellini W, Iori AP,
Boschetti C, Valle V, Frémeaux-Bacchi V, De Angioletti M, Socie G, Luzzatto L,
Notaro R: Polymorphism of the complement receptor 1 gene correlates with
hematological response to eculizumab in patients with paroxysmal nocturnal
hemoglobinuria. Haematologica 2013: . Epub ahead of print (Sept 13).
doi:10.1186/1756-8722-7-27
Cite this article as: Araten et al.: Selective splenic artery embolization for
the treatment of thrombocytopenia and hypersplenism in paroxysmal
nocturnal hemoglobinuria. Journal of Hematology & Oncology 2014 7:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
